322 related articles for article (PubMed ID: 30657438)
1. The prevalence of Healthcare Effectiveness Data and Information Set (HEDIS) initiation and engagement in treatment among patients with cannabis use disorders in 7 US health systems.
Lapham GT; Campbell CI; Yarborough BJH; Hechter RC; Ahmedani BK; Haller IV; Kline-Simon AH; Satre DD; Loree AM; Weisner C; Binswanger IA
Subst Abus; 2019; 40(3):268-277. PubMed ID: 30657438
[No Abstract] [Full Text] [Related]
2. Psychiatric comorbidity and Healthcare Effectiveness Data and Information Set (HEDIS) measures of alcohol and other drug treatment initiation and engagement across 7 health care systems.
Loree AM; Yeh HH; Satre DD; Kline-Simon AH; Yarborough BJH; Haller IV; Campbell CI; Lapham GT; Hechter RC; Binswanger IA; Weisner C; Ahmedani BK
Subst Abus; 2019; 40(3):311-317. PubMed ID: 30681938
[No Abstract] [Full Text] [Related]
3. The association between medical comorbidity and Healthcare Effectiveness Data and Information Set (HEDIS) measures of treatment initiation and engagement for alcohol and other drug use disorders.
Binswanger IA; Carroll NM; Ahmedani BK; Campbell CI; Haller IV; Hechter RC; McNeely J; Yarborough BJH; Kline-Simon AH; Satre DD; Weisner C; Lapham GT
Subst Abus; 2019; 40(3):292-301. PubMed ID: 30676892
[No Abstract] [Full Text] [Related]
4. Predictors of Healthcare Effectiveness Data and Information Set (HEDIS) treatment initiation and engagement among patients with opioid use disorder across 7 health systems.
Campbell CI; Weisner C; Binswanger IA; Lapham GT; Ahmedani BK; Yarborough BJH; Haller IV; Altschuler A; Hechter RC; Loree AM; Kline-Simon AH
Subst Abus; 2019; 40(3):328-334. PubMed ID: 30676931
[No Abstract] [Full Text] [Related]
5. Healthcare Effectiveness Data and Information Set (HEDIS) measures of alcohol and drug treatment initiation and engagement among people living with the human immunodeficiency virus (HIV) and patients without an HIV diagnosis.
Hechter RC; Horberg MA; Weisner C; Campbell CI; Contreras R; Chen LH; Yarborough BJH; Lapham GT; Haller IV; Ahmedani BK; Binswanger IA; Kline-Simon AH; Satre DD
Subst Abus; 2019; 40(3):302-310. PubMed ID: 30908174
[No Abstract] [Full Text] [Related]
6. Patient characteristics associated with treatment initiation and engagement among individuals diagnosed with alcohol and other drug use disorders in emergency department and primary care settings.
Kline-Simon AH; Stumbo SP; Campbell CI; Binswanger IA; Weisner C; Haller IV; Hechter RC; Ahmedani BK; Lapham GT; Loree AM; Sterling SA; Yarborough BJH
Subst Abus; 2019; 40(3):278-284. PubMed ID: 30702983
[No Abstract] [Full Text] [Related]
7. Factors associated with Healthcare Effectiveness Data and Information Set (HEDIS) alcohol and other drug measure performance in 2014-2015.
Weisner C; Campbell CI; Altschuler A; Yarborough BJH; Lapham GT; Binswanger IA; Hechter RC; Ahmedani BK; Haller IV; Sterling SA; McCarty D; Satre DD; Kline-Simon AH
Subst Abus; 2019; 40(3):318-327. PubMed ID: 30676915
[No Abstract] [Full Text] [Related]
8. Association between cannabis use disorder symptom severity and probability of clinically-documented diagnosis and treatment in a primary care sample.
Matson TE; Williams EC; Lapham GT; Oliver M; Hallgren KA; Bradley KA
Drug Alcohol Depend; 2023 Oct; 251():110946. PubMed ID: 37688980
[TBL] [Abstract][Full Text] [Related]
9. The importance of identification when measuring performance in addiction treatment.
Garnick D; Horgan C; Mark TL; Lee M; Acevedo A; Neager S; O'Brien P; Hashmi A; Marder B; Miller K
Subst Abus; 2019; 40(3):263-267. PubMed ID: 30913002
[No Abstract] [Full Text] [Related]
10. Medical conditions of primary care patients with documented cannabis use and cannabis use disorder in electronic health records: a case control study from an academic health system in a medical marijuana state.
Padwa H; Huang D; Mooney L; Grella CE; Urada D; Bell DS; Bass B; Boustead AE
Subst Abuse Treat Prev Policy; 2022 May; 17(1):36. PubMed ID: 35527269
[TBL] [Abstract][Full Text] [Related]
11. Predictors of substance use treatment initiation and engagement among adult and adolescent Medicaid recipients.
Lind BK; McCarty D; Gu Y; Baker R; John McConnell K
Subst Abus; 2019; 40(3):285-291. PubMed ID: 30759050
[No Abstract] [Full Text] [Related]
12. Prevalence and correlates of treatment utilization among adults with cannabis use disorder in the United States.
Wu LT; Zhu H; Mannelli P; Swartz MS
Drug Alcohol Depend; 2017 Aug; 177():153-162. PubMed ID: 28599214
[TBL] [Abstract][Full Text] [Related]
13. Predictors of treatment utilization and barriers to treatment utilization among individuals with lifetime cannabis use disorder in the United States.
Kerridge BT; Mauro PM; Chou SP; Saha TD; Pickering RP; Fan AZ; Grant BF; Hasin DS
Drug Alcohol Depend; 2017 Dec; 181():223-228. PubMed ID: 29107786
[TBL] [Abstract][Full Text] [Related]
14. Patient and System Characteristics Associated with Performance on the HEDIS Measures of Alcohol and Other Drug Treatment Initiation and Engagement.
Yarborough BJH; Chi FW; Green CA; Hinman A; Mertens J; Beck A; Horberg M; Weisner C; Campbell CI
J Addict Med; 2018; 12(4):278-286. PubMed ID: 29557802
[TBL] [Abstract][Full Text] [Related]
15. State Cannabis Legalization and Cannabis Use Disorder in the US Veterans Health Administration, 2005 to 2019.
Hasin DS; Wall MM; Choi CJ; Alschuler DM; Malte C; Olfson M; Keyes KM; Gradus JL; Cerdá M; Maynard CC; Keyhani S; Martins SS; Fink DS; Livne O; Mannes Z; Sherman S; Saxon AJ
JAMA Psychiatry; 2023 Apr; 80(4):380-388. PubMed ID: 36857036
[TBL] [Abstract][Full Text] [Related]
16. Relationship of Cannabis Use Disorder and Irritable Bowel Syndrome (IBS): An Analysis of 6.8 Million Hospitalizations in the United States.
Patel RS; Goyal H; Satodiya R; Tankersley WE
Subst Use Misuse; 2020; 55(2):281-290. PubMed ID: 31573379
[No Abstract] [Full Text] [Related]
17. Cannabis use disorder among veterans: Comorbidity and mental health treatment utilization.
Ecker AH; Lang B; Hogan J; Cucciare MA; Lindsay J
J Subst Abuse Treat; 2020 Feb; 109():46-49. PubMed ID: 31856950
[TBL] [Abstract][Full Text] [Related]
18. DSM-5 cannabis use disorder, substance use and DSM-5 specific substance-use disorders: Evaluating comorbidity in a population-based sample.
Hayley AC; Stough C; Downey LA
Eur Neuropsychopharmacol; 2017 Aug; 27(8):732-743. PubMed ID: 28663122
[TBL] [Abstract][Full Text] [Related]
19. Cannabis use disorder among people using cannabis daily/almost daily in the United States, 2002-2016.
Santaella-Tenorio J; Levy NS; Segura LE; Mauro PM; Martins SS
Drug Alcohol Depend; 2019 Dec; 205():107621. PubMed ID: 31698323
[TBL] [Abstract][Full Text] [Related]
20. Comorbid Cannabis and Tobacco Use Disorders in Hospitalized Patients with Psychotic-Spectrum Disorders.
Reeves LE; Gaudiano BA; Metrik J; Guzman Holst C; Morena A; Sydnor VJ; Weinstock LM; Epstein-Lubow G
J Dual Diagn; 2018; 14(3):171-180. PubMed ID: 30265850
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
